started · updated
ENBIOSIS launches AI-designed eye health supplement in Turkey
ENBIOSIS, a UK-based biotechnology company founded by Turkish entrepreneurs, has launched en-TEAR in the Turkish market. The supplement, designed using Digital Twin and artificial intelligence technologies, focuses on the connection between the gut microbiome and eye health.
A pilot clinical study conducted at Istanbul Medipol University, with ethics committee approval, evaluated the formula. According to ENBIOSIS Medical Director Dr. Varol Tunalı, the study observed a 67 percent increase in tear production among participants over an eight-week period. Notably, the researchers reported that this increase persisted until the 16th week, even after the regular use of the product had ceased, correlating with changes in the gut microbiome.
The pilot study involved 20 adults with dry eye complaints. To further validate these preliminary findings, the company is currently conducting a larger, randomized, double-blind, and placebo-controlled study involving 130 participants.